OliX Pharmaceuticals Inc (KOSDAQ:226950), a pharmaceutical company based in South Korea, said on Wednesday that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to develop its RNAi therapeutic OLX10212 for the treatment of age-related macular degeneration (AMD).
OLX10212 targets inflammation pathways that play a key role in the development of geographic atrophy (GA) and neovascular AMD. The primary objective of the phase 1 study is to evaluate the safety and tolerability of OLX10212 in patients with AMD.
With the FDA approval of the IND application for OLX10212, OliX has initiated clinical trials for two investigational therapeutic programmes in the US. In June 2022 the company completed patient enrolment for the Phase 2a clinical trial of OLX10010, for the treatment of hypertrophic scarring.
First Patient Dosed in Gamida-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
Bristol Myers Squibb and 2seventy bio Show Topline Results from KarMMa-3 Trial
Pfizer reports positive top-line results from Phase 3 study of IPD vaccine candidate
AstraZeneca granted US approval of Enhertu for HER2-mutant NSCLC
argenx announces EU approval of VYVGART for treatment of gMG
Roche's VENTANA MMR RxDx Panel receives US FDA label expansion approval